Shots: The companies signed a multi-year, multifaceted collaboration to develop novel Ab to treat & prevent various diseases including oncology and immunology The collaboration leverages H2L2 Harbour Mice platform to […]readmore
Tags : COVID-19
Shots: The collaboration supports the development of vaccines leveraging Heat’s gp96 platform designed to target SARS-CoV-2 coronavirus causing COVID-19 Heat’s subsidiary Zolovax will focus on the development of COVID-19 vaccines […]readmore
Shots: The companies expand their existing collaboration to develop & commercialize RNAi therapies targeting SARS-CoV-2 utilizing Alnylam’s advances in lung delivery of novel conjugates of siRNA along with Vir’s infectious […]readmore
Shots: Takeda initiates the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), TAK-888 for the treatment of high-risk individuals with COVID-19 and evaluates its marketed and pipeline products as viable […]readmore
Shots: The studies will evaluate 5-day and a 10-day dosing regimen of remdesivir (IV). One study will assess remdesivir + SOC in ~400 patients in a ratio (1:1) with sev. […]readmore
Shots: The companies will jointly develop, manufacture & commercialize Vir’s Ab. WuXi Biologics will conduct cell-line development, process & formulation development and initial manufacturing for clinical development Following the regulatory […]readmore
Shots: Codagenix will utilize its deoptimization technology for viral deoptimization, designed several nCoV vaccine candidate genomes, will grow and conduct in-vivo tests of vaccine viruses prior to testing in clinical […]readmore